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The human endogenous retrovirus-K113 (HERV-K113) is the most complete HERV known to date. It contains open reading frames for all viral
proteins. Depending on ethnicity, up to 30% of the human population carries the provirus on chromosome 19. To facilitate molecular and
functional studies, we have cloned the HERV-K113 sequence into a small plasmid vector and characterized its functional properties. Here we show
that based on a substantial LTR-promoter activity, full length messenger RNA and spliced env-, rec- and 1.5 kb (hel)-transcripts are produced. The
envelope protein of HERV-K113 is synthesized as an 85 kDa precursor that is found partially processed. The accessory Rec protein is highly
expressed and accumulates in the nucleus. Expression analysis revealed synthesis of the Gag precursor and the protease. However, the cloned
HERV-K113 provirus is not replication competent. It carries inactivating mutations in the reverse transcriptase gene. These mutations can be
reversed to reconstitute the active enzyme, but the reversion is not sufficient to reconstitute replication capacity of the virus.
© 2007 Elsevier Inc. All rights reserved.Keywords: Human endogenous retrovirus; HERV-K; Reverse transcriptase; Polymorphism; Envelope; RecIntroduction
The human chromosomes harbor N98,000 HERV (human
endogenous retrovirus) elements representing over 8% of the
genome (Bannert and Kurth, 2004; de Parseval and Heidmann,
2005). The majority of these sequences originate in germ line
infections of ancient exogenous retroviruses and several of these
proviruses then increased in number by germ line reinfection and
retrotransposition events leading to distinct sequence homology
groups, known as HERV families (Gifford and Tristem, 2003).
The members of most families have over 30 million years of
history of chromosomal residence and vertical transmission during
which they have undergone extensive deletions, recombinations
and mutations. Nevertheless, transcription and expression of ret-
roviral proteins as well as particle formation have been demon-
strated (Bieda et al., 2001; Lower et al., 1984). The observation⁎ Corresponding author. Fax: +49 4547 2334.
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tumors and tissues from patients with autoimmune diseases
suggests a role in the etiology or progression of these diseases
(Boller et al., 1997; Buscher et al., 2005; Christensen, 2005).
Most of the complete or almost complete proviral sequences
belong to the HERV-K(HML-2) family (Bannert and Kurth,
2006; Lower et al., 1993a; Ono et al., 1986). Their first members
integrated into the germ line of human and other Old World
primate ancestors about 35 million years ago. Throughout
evolution an ongoing acquisition and endogenization of HML-2
elements have taken place resulting in nearly 60 proviral copies
and an estimated 2500 solitary LTRs (Mager and Patrik, 2003).
There is substantial evidence that the predominant mode of
proliferation of this family was reinfection of the germ line by
replication competent viruses and that only this family has been
active to a considerable extent since the divergence of the human
and chimpanzee lineages 5–6 million years ago (Belshaw et al.,
2005b, 2004). There is even evidence that the mean insertional
rate before and after the human/chimpanzee split remained
almost the same (Belshaw et al., 2005b). Recent publications
report at least 73 human specific elements of which 15–20 are
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et al., 2003;Macfarlane and Simmonds, 2004), but the formation
of corresponding infectious viral particles has not yet been
reported. However, a proof of HERV-K(HML-2) infectivity has
been recently provided by in silico generated consensus se-
quences based on some of these elements (Dewannieux et al.,
2006; Lee and Bieniasz, 2007).
Approximately 10% of the investigated human specific
HML-2 loci are insertionally polymorphic (Belshaw et al.,
2005a; Hughes and Coffin, 2004). Alleles with full length
elements, solitary LTRs, empty insertion sites or tandem repeats
are present. The young age of these proviruses is further
supported by the high degree of homology between both LTR
sequences (Turner et al., 2001). Reverse transcription and
integration lead to identical LTRs at the time a provirus forms
and the number of subsequently acquired unique mutations can
be used to estimate how long ago the provirus formed.
An HERV-K(HML-2) element known as HERV-K113 with
almost identical LTR sequences (indicating a very recent acqui-
sition) has been identified in a human BAC library by Turner
et al. (2001). This provirus is the only known HERV-K with
open reading frames for all viral proteins that lacks any
substitutions in known functionally critical amino acids. This
element is not fixed in the human population, which means that
alleles with an “empty” preintegration site on chromosome 19
exist. The prevalence of this provirus depends on ethnicity and
was found to be highest (up to 30%) in African populations
(Burmeister et al., 2004; Moyes et al., 2005; Turner et al., 2001).
The geographic prevalence pattern supports the hypothesis that
the initial germ line infection by this virus occurred in Africa
and was spread during the migration of African populations
north and eastward 150,000–200,000 ears ago (Turner et al.,
2001). In an extensive study testing UK Caucasians, only 4.2
percent were found to carry the sequence (Moyes et al., 2005).
An interesting finding is the 3 times higher frequency of HERV-
K113 in patients suffering from multiple sclerosis or Sjögren's
Syndrome in the UK compared to healthy donors. HERV-K113
may therefore be a risk factor for some types of autoimmunity
disorders (Moyes et al., 2005).
In the present study, we report the molecular cloning and
functional characterization of HERV-K113, one of the youngest
and best-preserved HERV-K(HML-2) elements. We have
analyzed the activity of its LTR promoter, the splicing pattern
of transcripts as well as the expression and function of most of itsFig. 1. Cloning strategy for HERV-K113. The sequence of the provirus present in the
cloned into a modified pBluescript II SK (+) vector (Stratagene) as four overlappingproteins. Finally, we investigated the replication ability of the
cloned provirus in transfected human cell lines and discuss the
pathogenic potential of this provirus.
Results
Molecular cloning of HERV-K113 into a small plasmid vector
In order to generate a small plasmid vector containing the
complete HERV-K113 provirus present in the BAC clone de-
scribed by Turner et al. (2001), we amplified four overlapping
fragments covering the entire 9472 bp long provirus sequence
with additional 186 nt upstream and 102 nt downstream of
the integration site on chromosome 19p13.11 (Fig. 1). The
fragments were subsequently cloned into a modified pBluescript
II SK (+) plasmid reassembling the complete provirus in the new
vector pBSK-HERV-K113. The sequential cloning strategy was
used because all our attempts to insert the PCR amplified
complete sequence failed. The successfully cloned provirus has
been completely sequenced. No differences to the sequence in
the GenBank accession no. AY037928 were found.
Activity of the HERV-K113 promoter
To analyze the activity of the LTR promoter in human cells,
the region encoding the entire HERV-K113 LTR was inserted
upstream of the luciferase gene in a reporter vector (Fig. 2A). A
reporter gene activity, more than twice as high as that of the
corresponding HERV-K10 sequence was measured in lysates of
transfected HEK 293T (Fig. 2B) and HeLa (data not shown) cell
lines. Extension of the LTR sequence up to the major splice
donor site did not result in a significant change in reporter gene
expression. The activity of the HERV-K113 promoter was only
10 times lower than that of the commonly used SV40 virus
promoter. A high expression in 293T cells was also driven by
the promoter of the Koala retrovirus, which is able to replicate
in human cells (Fiebig et al., 2006). Taken together, the results
demonstrate that the HERV-K113 promoter retains the capacity
to initiate significant transcription in human cells.
Detection of HERV-K113 transcripts
The substantial activity of the LTR promoter in reporter gene
constructs suggests active transcription of the cloned provirus.BAC clone RP11-398B1 (Turner et al., 2001) was amplified and subsequently
fragments (I–IV) using the restriction sites indicated.
Fig. 2. Determination of the promoter activity of the cloned HERV-K113 provirus. (A) The indicated sequences of HERV-K113 containing the entire LTR region as
well as corresponding regions of HERV-K10 and KoRV were inserted into a luciferase reporter vector. (B) Normalized reporter gene activities in lysates of transfected
cells. The data are means and standard deviations of a representative experiment performed in triplicate. The empty pGL3Basic vector was used to determine the
background reporter activity.
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were transiently transfected with pBSK-HERV-K113, the cor-
responding empty vector and the large parental BAC clone.
Using an RT-PCR approach with specific primers, spliced env
and rec RNAs were easily detected in cells transfected with the
pBSK-HERV-K113 (Fig. 3A). No env-transcripts were ampli-
fied from cells that received the empty vector pBluescript II SK
(+) or the BAC clone. A faint rec-specific signal was, however,
present in pBluescript II SK (+) and BAC-transfected HEK 293TFig. 3. Analysis of HERV-K113 transcripts. (A) An RT-PCR with specific primer pa
cells was performed. Expected splice products and position of the primers are depic
HERV-K113 (lanes 2+6), pBluescript II SK (+) (lanes 3+7) and no RNA control (
HERV-K113 show the expected specific amplification signals of 602 nt correspondin
mRNA (lane 6). Aweak rec-specific signal was present in cells transfected with the o
low endogenous rec transcription from one or more genomic proviruses. No endoge
reactions lacking RNA for the env (lane 4) and rec (lane 8) RT-PCR were included
pBSK-HERV-K113 transfected (lane 2) HEK 293Tcells. Total RNA from Tera-1 cells
site of the probe corresponds to a sequence upstream of the major splice donor sitecells indicating a low background of chromosomally encoded
rec-transcripts in these cells. Sequencing of the amplified
HERV-K113 cDNA revealed the position of the splice sites. For
the generation of the env-transcripts, the splice donor at nt
position 1076 and the splice acceptor at nt 6433 are used. For the
second splice event leading to rec transcripts, the splice donor at
nt 6711 and splice acceptor at nt 8410 are utilized.
To further characterize the transcription of HERV-K113,
Northern Blots were performed using a 477 nt sequenceirs for the detection of spliced HERV-K113 transcripts in transfected HEK 293T
ted in the upper panel. Transfections: pBAC-RP11-398B1 (lanes 1+5), pBSK-
lanes 4 and 8). Cells transfected with the molecular HERV-K113 clone pBSK-
g to singly spliced env mRNA (lane 2) and of 406 nt for the doubly spliced rec
riginal BAC clone (lane 5) or with an empty control vector (lane 7), indicating a
nous (lane 3) or BAC clone born (lane 1) env-transcripts were detected. Control
. (B) Northern Blot experiments with 5 μg total RNA from native (lane 1) and
, known to express HERV-K, was used as a positive control (lane 3). The binding
(nt 595–1072).
Fig. 5. Replication assay in HOS cells stably expressing CD4 and CXCR4. Cells
were transfected with pBSK-HERV-K113, pNL4-3 and an empty control
vector (pBluescript II SK (+)). Supernatants were collected over a period of
3 weeks, filtered through a 45 μm membrane before the RT-activity was deter-
mined. The data represent means of an experiment done in triplicate. For HERV-
K113 and the vector control, only the plus standard deviations are depicted.
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sequence is thought to be present in all HERV-K transcripts.
Three major bands corresponding to the size of the full length
transcript (8.9 kb) and the spliced mRNAs coding for Env
(3.5 kb) and Rec (1.8 kb) were detected (Lower et al., 1993a). A
fourth, fainter signal of 1.5 kb was most likely the poorly
described hel-transcript. As each of these mRNAs originates
from one complete provirus, the 1.5 kb mRNA is obviously not
an artificial transcript of an incomplete proviral sequence.
HERV-K113 therefore produces all transcripts of a class II
HERV-K(HML-2) previously described (Lower et al., 1984).
Expression of viral proteins
In a first attempt to study the expression of HERV-K113
proteins, the coding regions were cloned as C-terminally tagged
sequences into the eukaryotic expression vector pcDNA3-V5.
Using a V5-tag specific monoclonal antibody, a Gag protein of
about 80 kDa and a putative protease with an apparent molecular
weight of 43 kDa were detected in lysates of transfected HEK-
293T cells (Fig. 4A). We were able to detect neither the CMV
promoter-driven expression of V5-tagged polymerase nor the
Gag-Pro-Pol-polyprotein or C-terminal processing fragments
thereof, probably due to low expression levels or a poor stabilityFig. 4. Expression of proteins encoded by HERV-K113. (A) The reading frames codin
aC-terminalV5-tag. The proteinswere expressed inHEK293Tcells and immunoblotted us
could be detected. (B) Immunoblot using a transmembrane protein (TM)-specific antiserum
detectable in lane 1whichwas loadedwith lysates of cells expressing the Env-V5 protein. T
transfected with pBSK-HERV-K113. (D) Specific detection of the Rec-V5 protein on aWe
cells transfected with pBSK-HERV-K113. A Rec-specific antiserum generated in rabbitsof these proteins. The low expression of the large Gag-Pro-Pol-
precursor was likely because its synthesis requires two ribo-
somal frame shifts in the −1 direction to read through the stops ing for the proteins of the provirus were cloned into the pcDNA3 vector containing
ing aV5 specific antibody.NoPol-V5 andGag-Pro-Pol-V5 fusion protein expression
. Protein bands of the expected size for the envelope precursor (Env) and the (TM) are
hese signals aremissing inmock transfected cells (lane 2). (C) Env expression in cells
stern blot (left panel) and by immunofluorescence (right panel). (E) Rec expression in
was used for the immunofluorescence. Nuclei are stained blue with DAPI.
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related betaretrovirus mouse mammary tumor virus (MMTV),
this can be expected in only 2–3% of all Gag-translations (Jacks
et al., 1987).
In cells expressing HERV-K113 Env-V5, proteins of
approximately 85 and 40 kDa are visible. After longer exposure,
an additional band at 72 kDa appears (not shown). The 85 kDa
protein corresponds to the previously reported molecular mass
of the glycosylated envelope precursor of HERV-K108
(Dewannieux et al., 2005). The theoretical value for the non-
glycosylated precursor devoid of the signal peptide is 68 kDa.
The 40 kDa band represents the putative glycosylated
transmembrane protein (theoretical value for the unglycosylated
form is 26 kDa). This 40 kDa protein and the 85 kDa precursorFig. 6. Reactivation of the polymerase by site directed mutagenesis. (A) Alignment of
six positions in the HERV-K113 sequence changed into the amino acids of HERV-K1
HERV-K113 RTand the mutated K113 mutRT version containing the six amino acid s
first (mutRT1–3) and last three (mutRT4–6) mutations only. A reticulocyte based inare also detected by a specific antiserum raised against the
ectodomain of the HERV-K transmembrane protein (Fig. 4B).
Using a commercially available monoclonal antibody against
the envelope protein, the unprocessed precursor of 85 kDa can
be detected in lysates of cells transfected with the molecular
clone (Fig. 4C).
The HERV-K Rec protein is a nuclear shuttle protein that
accumulates in nucleoli and facilitates viral RNA transport
(Magin et al., 1999). Of special interest is its association with
germ cell tumors and other malignancies (Boese et al., 2000).
The Rec-Protein of HERV-K113 migrates with an apparent
molecular mass of about 15–17 kDa in Western blots (Fig. 4D,
left panel). Using a specific antiserum, we could demonstrate
Rec protein accumulating in particular regions of the nucleus ofthe RT sequences of HERV-K113 and HERV-K10.1 (Berkhout et al., 1999). The
0.1 are shown in frames. (B) RT activity in lysates of cells expressing the original
ubstitutions. (C) Incomplete reactivation of the RTactivity by introduction of the
vitro translation/transcription system was used to express the proteins.
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Rec-V5 plasmid (Fig. 4D, right panel) or with the molecular
clone pBSK-HERV-K113 (Fig. 4E), but not in mock transfected
control cells (not shown).
Replication in cell lines transfected with the molecular clone
HERV-K particles have been observed in several tissues and
cell lines including teratocarcinomas and melanomas but active
replication of a HERV-K element has not yet been reported
(Bieda et al., 2001; Muster et al., 2003). In order to determine
the replication potential of the cloned HERV-K113, HOS cells
expressing CD4 and CXCR4 were transfected with pBSK-
HERV-K113, pNL4-3 (which contains the full sequence of a
T-tropic HIV-1 strain) and the empty vector control pBluescript
II SK (+). In contrast to pNL4-3 transfected cells, no RT activity
in the supernatants of cells transfected with the plasmid
containing the HERV-K113 provirus was evident up to day 21
post transfection (Fig. 5). Similar results were obtained with
HeLa, HEK-293T, GH, Tera-1, SK-Mel28 and canine Cf2Th
cell lines in experiments running up to 48 days. We therefore
conclude that the cloned HERV-K113 sequence does not encode
infectious virus particles able to establish productive replication.
Activity of the HERV-K113 reverse transcriptase
The inability of HERV-K113 to replicate in human cell lines
prompted us to determine the enzymatic activity of its RT. The
HERV-K113 region corresponding to the sequence of the active
HERV-K10.1 enzyme (Berkhout et al., 1999) was cloned and
expressed in HEK 293Tcells. In addition, a version of the HERV-
K113 RT with amino acids at six different positions changed to
those present in the active HERV-K10 enzyme (Fig. 6A) was
generated and expressed in parallel. No RT activity was detected
in lysates of cells transfected with the vector containing the
original HERV-K113 RT. In contrast, a significant RT activity,
more than 10 times above the background, was evident in cells
expressing the mutated enzyme HERV-K113mutRT (Fig. 6B).
This demonstrates that the RTencoded by the clonedHERV-K113
provirus is not functional, but its activity can be reconstituted.
Using an in vitro transcription translation system, the activity of
enzymes containing the first and the last three mutations was
compared with the fully mutated enzyme. Neither of the partially
mutated proteins reached the activity of the RT with all six
exchanges (Fig. 6C). We therefore conclude that more than a
single amino acid substitution is necessary to recover the full
activity of the mutRT enzyme.
The six mutations that reconstitute RT activity were then
introduced into the molecular clone by site directed mutagenesis
to test whether an active RT is produced in a proviral context and
allows the virus to replicate. HEK-293T, Tera-1 and the CD4,
CXCR4 expressing HOS cells were subsequently transfected
with the modified molecular clone. However, no RT activity
could be demonstrated in two independent experiments done in
triplicate over a period of 21 days in any of the supernatants (data
not shown). Thus, the reconstitution of an active RT enzyme in
the sequence of the cloned provirus is not sufficient to produceparticle associated RTactivity. In addition, no RTactivity and no
envelope protein could be detected in pellets obtained by
ultracentrifugation of supernatants two days post infection with
pBSK-HERV-K113mutRT carrying the mutated RT sequence
(data not shown). The lack of envelope protein is consistent with
a previous report showing a defect in the incorporation of the
HERV-K113 envelope proteins into retroviral particles (Dewan-
nieux et al., 2005). We therefore conclude that an inefficient
particle formation, impaired synthesis of the Gag-Pro-Pol
precursor and a lack of envelope protein incorporation are key
factors in HERV-K113's loss of replication capacity.
Discussion
Of all human endogenous retrovirus families, HERV-K
(HML-2) contains the youngest and best preserved members
(Mager and Patrik, 2003;Mayer andMeese, 2005). However, no
proviral sequence in the human genome has yet been described
that has the potential to form replication competent particles.
The infectivity of two recently in silico generated HERV-K
consensus sequences based on human specific loci demonstrates
the principle ability of HERV-K(HML-2) to produce retroviral
particles that infect present-day human and non-human cells
(Dewannieux et al., 2006; Lee and Bieniasz, 2007).
To investigate the activity of the HERV-K113, the only
known HERV-K(HML-2) provirus with completely open
reading frames and preserved essential protein domains, we
amplified and subcloned the proviral sequence from a large
BAC vector (Turner et al., 2001) into a small plasmid vector to
enable efficient transfection of mammalian cells.
The presence of spliced env- and rec-mRNA could be
demonstrated by RT-PCR using specific primers. Sequencing of
the amplified transcripts revealed that the expected splice donor
and acceptor sites were used (Mayer et al., 2004). The complete
transcripts and splicing pattern of HERV-K113 have been
determined by Northern blots with RNA from cells transfected
with the molecular clone. A full-length transcript of HERV-K113
was detected. This had a slightly larger size than the most pro-
minent full-length HERV-K bands in GH and Tera-1 cells. These
full length RNAs (approximately 8.6 kb long) in teratocarcinoma-
derived cell lines might represent subtype 1 proviruses that carry a
characteristic 292 nt deletion or are derived from a subset of
mutants with other short deletions (Armbruester et al., 2002;
Lower et al., 1993b). Of interest is the higher relative amount of
HERV-K113 specific env-transcripts compared to Tera-1 and GH
cells. Virus particles produced by most GH and Tera-1 cells are
characterized by a low envelope content and by poor processing
efficiency (Bieda et al., 2001). As can be expected for a subtype 2
HERV-K, the 1.8 kbp mRNA encoding the Rec protein is present.
In addition, an approximately 1.5 kb RNA was evident that
presumably represents the poorly described “hel” transcript.
Transcription of HERV-K113 is driven by the 5′-LTR pro-
moter. In the human 239Tcell line, it was only 10 times less potent
than the strong SV40 promoter and compared with the LTR of
HERV-K10 its activity was about two times higher. The 5′-LTR
of the cloned HERV-K113 virus differs from the 3′-LTR only
at three positions (nt 84, 295 and 629). At these positions, the
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Dewannieux and coworkers. We therefore conclude that the 5′-
LTR of HERV-K113 is completely preserved and represents the
original sequence of the provirus as it integrated. The three
differences between the two LTRs of the cloned HERV-K113
sequence were most likely introduced by postinsertional sub-
stitutions in the 3′-LTRs. Extension of the LTR up to the major
splice donor site did not result in a significant change in
promoter activity indicating the absence of major transcription-
ally active regulatory elements in this region or a neutralization
of positive and negative effects.
Using a specific antiserum, we could demonstrate Rec protein
at distinct sites in the nuclei of cells transfected with the
molecular clone. HERV-K113 Rec therefore shows the sub-
cellular localization previously described, a prerequisite for its
function in mediating nuclear export of incompletely spliced
HERV-K transcripts (Magin et al., 1999). Compared with the
two recently published consensus sequences, the protein differs
at only two amino acids encoded by exon 2, a threonine instead
of alanine at position 89 and glutamic acid instead of aspartic
acid at position 96. The first difference is most likely a result of a
mutation and not a natural variation among infectious viruses. G
to A is the most frequent change between HERV-K113 and the
nucleotide consensus sequence, hinting at a possible role for
cytidine deaminases in the generation of these exchanges (Lee
and Bieniasz, 2007). In addition, it substitutes a possibly critical
cysteine in the transmembrane region of the envelope protein for
tyrosine. In contrast, the glutamic acid at position 96 is probably
a natural variation since the underlying A to C change at the
nucleotide level occurs with a low frequency and is a con-
servative amino acid substitution leaving the envelope protein
encoded by one of the other reading frames unaffected. The two
differences with respect to the consensus sequence obviously do
not render the protein non-functional in terms of its ability to
transport partially spliced mRNAs out of the nucleus because
comparable amounts of rec- and env-transcripts are detectable in
Northern blots. A non-functional Rec protein would result in a
high level of rec and hel transcripts at the expense of env- and
full-length-mRNAs (Magin et al., 1999).
The detection of some of the HERV-K113 proteins in
transfected cells was hampered by the lack or by the low
specificity of the available antibodies. However, the expression
of C-terminally tagged Gag, protease and envelope proteins
driven by a CMV promoter could be demonstrated, with each
protein migrating with the expected sizes in immunoblots. In
cells expressing the envelope protein, bands of about 85 and
40 kDa, consistent with the sizes of the unprocessed glycosy-
lated C-terminally tagged precursor protein and transmembrane
subunit, are present (Dewannieux et al., 2005; Tonjes et al.,
1997). Partial processing, albeit of lower efficiency, has been
shown for envelope proteins of other HERV-K proviruses in cell
lysates and pseudotyped lentiviral particles (Dewannieux et al.,
2006). Despite cell surface expression, Dewanieux and
colleagues could not pseudotype lentiviral vectors with the
HERV-K113 envelope protein because of its inability to be
incorporated into lentiviral particles. In contrast the protein of
HERV-K108 was incorporated and functional (Dewannieuxet al., 2006). It seems therefore that an inherent defect precludes
insertion of the HERV-K113 envelope into retroviral particles.
In addition to an obviously crippled envelope, the reverse
transcriptase of HERV-K113 is also defective. No enzymatic
activity or protein could be detected in cells transfected with the
molecular clone or with a CMV promoter-driven expression
construct containing a C-terminal V5-tag for detection.
Consistent with this result, no replication activity of the cloned
provirus could be measured in a panel of cell lines tested. The
reverse transcriptase activity of the enzyme could be restored by
changing six amino acids into those present in the active
enzyme of a HERV-K10 provirus previously described (Berkh-
out et al., 1999). We have shown that at least two of the six
mutations do severely affect the activity of the enzyme. The
introduction of all six mutations into the RT sequence of the
molecular clone was, however, not sufficient to produce particle
associated RT activity, demonstrate envelope incorporation and
restore replication capacity.
Although the subcloned HERV-K113 provirus is due to mul-
tiple defects replication incompetent, the high sequence poly-
morphism at each HERV-K(HML-2) locus within the human
populations does not preclude the presence of a natural variant
with one or all of its proteins being functional (Dewannieux et al.,
2006). A deeper investigation into the polymorphism of HERV-
K113 and other young and most complete HERV-K(HML-2) loci
together with the unraveling of frequent inactivating mutations
will help to estimate the probability of a functional preservation in
some individuals and contribute to a better understanding of the
mechanisms and dynamics of endogenization and fixation of
retroviruses. Furthermore, infectious retroviruses could be theo-
retically generated in vivo by recombination between partially
incompetent proviruses (Dewannieux et al., 2006) and the
permanent presence of an infectious provirus in the population
is therefore not required to explain the approximately 35 million
years of HERV-K(HML-2) reinfections. These reinfections
continued in humans and chimpanzees after their ancestors split
5–6 million years ago and might not yet have completely and
irreversible stopped. The recently documented infection of human
cells by model HERV-K(HML-2) elements (Dewannieux et al.,
2006; Lee and Bieniasz, 2007) and the implications for the
development of some types of malignancies and autoimmune
diseases warrant further investigation.
Methods
Cell lines and transfection
All cell lines used were grown in Dulbecco's modified
Eagle's medium containing 10% fetal bovine serum supple-
mented with 100 units/ml penicillin, 100 μg/ml streptomycin
and 2 mM glutamine. Cells were transfected using PolyFect
Transfection Reagent (Qiagen).
Amplification and molecular cloning
The BAC clone RP11-398B1 containing the HERV-K113
provirus (Turner et al., 2001) was purchased from BACPAC
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lapping fragments of the proviral sequence were amplified by
PCR using the Expand High Fidelity PCR System (Roche) and
the BAC clone as template. The fragments were cut with
restriction enzymes (Fig. 1) and cloned in reverse order (fragment
4 first) into the pBluescript II SK (+) phagemid (Stratagene) to
generate the vector pBSK-HERV-K113. To insert fragment 4, the
SacI site in the multiple cloning site of the plasmid was moved
between the SpeI and NotI sites by site directed mutagenesis.
The promoter sequences of HERV-K113 and HERV-K10
(Ono et al., 1986) were amplified by standard PCR reac-
tions using the oligonucleotides 113_f (5′-CGCCGGTACCG-
TAGTCATCTTGTTGAAATGATTTGCCTTG-3′) and
113_r984 (5′-ACTGACCTCGAGCACGTTGGGCACCA-
GATGTAG-3′) for the HERV-K113 LTR up to position 984
and 113f and 113r1072 (5′-ACTGACCTCGAGAGGCTGACT-
GTAGACGTACTCG-3′) for the sequence up to position 1072.
The HERV-K10 LTR was amplified with the primer pair 10_f
(5′-ACTGACGGTACCTCACTCTGTCACCCAGGCTGG-
GGTG-3′) and 10_r (5′-ACTGACAAGCTTAAGGCTGACT-
GTA GATGTACTCGG-3′). The amplified sequences were
cloned into the pGL3-Basic vector (Promega).
Open reading frames of the HERV-K113 proteins Gag, Pro,
Pol and Env and the region coding for the Gag-Pro-Pol poly-
protein were amplified using the Pfu polymerase and the
following primer pairs: Gag: gag_f (5′-ACGCAGGGATCCGC-
CATGGGGCAAACTAAAAGTAAAATTAAAAG-3′) and
gag_r (5′-TTGATCATCGCGGCCGCCTGCTGCACT-
GCCGCTTGTGGCGG-3′); Pro: pro_f (5′-ACGCAGG-
GATCCGCCATGAAATGGGCAACCATTGTCGG-3′) and
pro_r (5′-TTGCAGTCGGCGGCCGCAAAAGGATACCC-
TATTCCTTCTC-3′); Pol: pol_f (5´-ACGCAGGGATCCG-
CCATGAAATCAAGAAAGAGAAGGAATAG-3′ and pol_r
(5′-TTGCAGTCGGCGGCCGCAAGCATGAAGTTCT-
TGTGCTTTTATG-3′); Env: env_f (5′-ACGTCGAAGCTTGC-
CATGAACCCATCGGAGATGCAAAGAAAAG-3′) and env_r
(5′-TTGCAGTCGGCGGCCGCCACAGACACAGTAA-
CAATCTGATCTC-3′); Gag-Pro-Pol: gag_f and pol_r. The
amplified sequences were inserted into the pcDNA3-V5 vector
as described previously (Bannert et al., 2003).
To clone the Rec coding region, total RNA from HEK 293T
cells transfected with the pBSK-HERV-K113 plasmid was
isolated. This was used in a one step RT-PCR reaction with the
oligonucleotides rec_f (5′-ACGTCGAAGCTTGCCATGAACC-
CATCGGAGATGCAAAG-3′) and rec_r (5′-TTGCAGTC-
GGCGGCCGCTGGCCCGTTCTCGATGGTCGCTGTC-3′) to
amplify the rec cDNA. The amplified sequence was inserted into
the pcDNA3-V5 vector.
Detection of HERV-K113 transcripts
Total RNA was isolated from HEK-293T cells 2 days after
transfection with the HERV-K113 molecular clone. An RT-PCR
using the One Step RT-PCR-Kit (Qiagen) with 25 cycles and
an annealing temperature of 54°C was run with the isolated
RNA as template. The oligonucleotide F (5′-TTTCTCTAG-
GGTGAAGGTACGC-3′), as forward primer, and R2 (5′-GTTCTCGATGGTCGCTGTCTC-3′) or R1 (5′-TGGT-
GCTCTCCCTAGGCAAATAG-3′), as reverse primer, were
added to detect Rec- and Env-coding transcripts, respectively.
Promoter activity assay
HEK 293T and HeLa cells were transiently transfected in 6-
well-plates. Two days post transfection, cells were treated with
CCRL lysis buffer (Luciferase Assay System, Promega) and
luciferase activity was measured in cleared supernatants with a
TECANGENios Pro luminometer (Tecan). A plasmid expressing
a secreted alkaline phospatase was cotransfected for normaliza-
tion of the data.
Northern blot analysis
ForNorthernBlot experiments, 5μg total RNAwas loaded on a
formaldehyde gel and separated at 50 V. After transferring the
RNA onto a positively charged nylon membrane (Roche) by
overnight-capillary blotting, the sampleswere cross linked by UV-
light. Twenty-five nanograms of linearized DNA template (nt
595–1072) was used for probe synthesis and labeled with [α32P]
dATP (3000 Ci/mmol, 10 mCi/ml) by random priming as de-
scribed in the Strip-EZ DNA protocol (Ambion). After overnight
hybridization at 42 °C, the signals were detected with a phos-
phoimager or a commercial X-ray film. To demonstrate com-
parable RNA load, the membrane was stripped according to the
manufacturer's instructions and rehybridized with an actin probe.
Detection of HERV-K113 proteins
HEK 293T cells were transfected in 10-cm dishes. Two days
post transfection, cells were treated with lysis buffer (1% Triton
X-100, 50 mM Tris–HCl, pH 7.5, 150 mM NaCl, 5 mM EDTA
and protease inhibitor mix) for 20 min at 4 °C followed by
centrifugation to remove cell debris. The supernatant was
separated on SDS-polyacrylamide gels, transferred to poly-
vinylidene difluoride membranes (Bio-Rad) and detected by
standard Western blotting procedure using enhanced chemilu-
minescence (ECL, Amersham Biosciences). The monoclonal
anti-V5-HRP was purchased from Invitrogen, the TM specific
antiserum was kindly provided by Joachim Denner (Robert
Koch-Institute) and the anti-HERV-K envelope antibody was
purchased from Austral Biologicals.
For the detection of particle associated envelope protein,
supernatants from transfected cells were cleared by low spin
centrifugation on day 2 post transfection. Pellets obtained after
ultracentrifugation through a 20% sucrose cushion at 72,000×g
for 3 h at 4 °C were immunoblotted using the HERV-K envelope
specific antibody.
Immunofluorescence microscopy
Cells were grown in 6-well plates, transfected with PolyFect
Reagent (Qiagen) and transferred the next day into Lab-Tek
chamber slides (Nalge Nunc). Twenty-four hours later, cells
were fixed with 2% formaldehyde (Sigma) in PBS for 30 min,
224 N. Beimforde et al. / Virology 371 (2008) 216–225rinsed briefly in PBS, permeabilized with 0.5% Triton X-100 in
PBS for 15 min and washed 3 times with PBS. After a 30 min
incubation with blocking buffer (PBS with 1% Marvel non-fat
milk), cells were incubated with the primary antibodies or
antisera diluted in blocking buffer for 60 min at 37 °C. The
slides were washed extensively with PBS and the secondary
antibodies conjugated to fluorophores were added for 30 min.
Nuclei were stained with DAPI. After thorough washing steps
with PBS, the cells were mounted in Mowiol. The Rec-specific
antiserum was kindly donated by Roswitha Löwer (Paul-
Ehrlich-Institut). Images were obtained on a Zeiss (LSM510)
confocal laser scanning microscope.
Replication-assay and determination of RT activity
Supernatants of transfected cells were collected for up to
48 days, filtered through membranes (45 μm pore size) and
assayed for RT activity using the CAVIDI HS-kit Mg2+ RT
(Cavidi Tech AB, Uppsala, Sweden) according to the manufac-
turer's instructions.
The activity of the different RT mutants was determined by
expression of the proteins using the reticulocyte based TNT T7
Quick Coupled Transcription/Translation System (Promega)
followed by the Cavidi RT assay.
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